Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
Francesca Poggio(Ospedale Policlinico San Martino), Lucia Del Mastro(Ospedale Policlinico San Martino), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Fabio Puglisi(University of Udine), Anita Rimanti(Azienda Ospedaliera Carlo Poma), G. Colantuoni(Azienda Ospedaliera S.Giuseppe Moscati), Pierpaolo Correale(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Emanuela Magnolfi(Accademia di Belle Arti di Frosinone), Eva Blondeaux(Ospedale Policlinico San Martino), Piero Fregatti(University of Genoa), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), C. Nisticò(Accademia di Belle Arti di Frosinone), Simona Gasparro(National Cancer Institute), Grazia Arpino(University of Naples Federico II), Alessandra Fabi(Agostino Gemelli University Polyclinic), M.G. Alicicco(Azienda Ospedaliero Universitaria di Sassari), Giancarlo Bisagni, Benedetta Conte(Ospedale Policlinico San Martino), Mario Giuliano(Regione Campania), Simone Nardin(Ospedale Policlinico San Martino), Anna Turletti(Ospedale Martini), Chiara Molinelli(Ospedale Policlinico San Martino), Marco Tagliamento(Ospedale Policlinico San Martino), Luca Boni(Ospedale Policlinico San Martino), Matteo Lambertini(Ospedale Policlinico San Martino), Ylenia Urracci, Paola Poletti(Ospedale Papa Giovanni XXIII), Adriano Gravina(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandra Fozza(Ospedale Policlinico San Martino), Marta Perachino(Ospedale Policlinico San Martino)
Cited by 5
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830